Plasma Metabolomics Identified Novel Metabolites Associated with Risk of Type 2 Diabetes in Two Prospective Cohorts of Chinese Adults.

Gaokun Qiu,Yan Zheng,Hao Wang,Jie Sun,Hongxia Ma,Yang Xiao,Yizhun Li,Yu Yuan,Handong Yang,Xiulou Li,Xinwen Min,Ce Zhang,Chengwei Xu,Yue Jiang,Xiaomin Zhang,Meian He,Ming Yang,Zhibin Hu,Huiru Tang,Hongbing Shen,Frank B. Hu,An Pan,Tangchun Wu
DOI: https://doi.org/10.1093/ije/dyw221
IF: 9.685
2016-01-01
International Journal of Epidemiology
Abstract:Background: Metabolomics studies in Caucasians have identified a number of novel metabolites in association with the risk of type 2 diabetes (T2D). However, few prospective metabolomic studies are available in Chinese populations. In the present study, we sought to identify novel metabolites consistently associated with incident T2D in two independent cohorts of Chinese adults.Methods: We performed targeted metabolomics (52 metabolites) of fasting plasma samples by liquid chromatography-mass spectrometry in two prospective case-control studies nested within the Dongfeng-Tongji (DFTJ) cohort and Jiangsu Non-communicable Disease (JSNCD) cohort. After following for 4.61 +/- 0.15 and 7.57 +/- 1.13 years, respectively, 1039 and 520 eligible participants developed incident T2D in these two cohorts, and controls were 1: 1 matched with cases by age (+/- 5 years) and sex. Multivariate conditional logistic regression models were constructed to identify metabolites associated with future T2D risk in both cohorts.Results: We identified four metabolites consistently associated with an increased risk of developing T2D in the two cohorts, including alanine, phenylalanine, tyrosine and palmitoylcarnitine. In the meta-analysis of two cohorts, the odds ratios (95% confidence intervals, CIs) comparing extreme quartiles were 1.79 (1.32-2.42) for alanine, 1.91 (1.41-2.60) for phenylalanine, 1.85 (1.37-2.48) for tyrosine and 1.63 (1.21-2.20) for palmitoylcarnitine ( all P-trend <= 0.01).Conclusions: We confirmed the association of alanine, phenylalanine and tyrosine with future T2D risk and further identified palmitoylcarnitine as a novel metabolic marker of incident T2D in two prospective cohorts of Chinese adults. Our findings might provide new aetiological insight into the development of T2D.
What problem does this paper attempt to address?